AN2 Therapeutics (ANTX) Profit After Tax (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Profit After Tax data on file, last reported at -$10.1 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 5.1% year-over-year to -$10.1 million in Q1 2026; TTM through Mar 2026 was -$34.5 million, a 23.36% increase from a year earlier, with the FY2025 full-year figure at -$35.1 million, up 31.51% from the prior year.
• Profit After Tax for Q1 2026 stood at -$10.1 million, down from -$8.6 million in the prior quarter.
• Over the last five years, Profit After Tax for ANTX reached as high as -$6.5 million in Q2 2025 and fell as low as -$17.2 million in Q4 2023.
• Historically, Profit After Tax has averaged -$11.9 million across 5 years, with a median of -$11.3 million in 2022.
• Across the five-year window, Profit After Tax plunged 273.78% in 2022 and surged 57.09% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$11.8 million in 2022, then slumped by 44.82% to -$17.2 million in 2023, then jumped by 57.09% to -$7.4 million in 2024, then fell by 17.52% to -$8.6 million in 2025, then declined by 16.67% to -$10.1 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$10.1 million in Q1 2026, -$8.6 million in Q4 2025, and -$9.3 million in Q3 2025.